Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Erbitux meets NSCLC Phase III endpoint

Merck KGaA (FSE:MRK) said first-line therapy with Erbitux cetuximab plus

Read the full 108 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE